Quantum Leap Healthcare Collaborative
The I-SPY Trials
For Patients
ABOUT
I-SPY 2 Trial
Resources
Funding & Support
Agents & Results
I-SPY Agents
Manuscripts
Meeting Abstracts
Collaborate
Proposal Submissions
Partner With Us
News
Latest News
Feature Articles
I-SPY in the News
Media Center
People
Leadership
Clinical Sites
Contact Us
FOR PATIENTS
News
Press Releases
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Close
Close
Close
I-SPY Email List Sign-up
First Name:
Last Name:
Email Address:
Breast cancer patient/family/friend
Research/Medical Professional
Just Interested
Thank you, your subscription is activated.
If you change your mind, you can
unsubscribe
at any time.
Oops! Something went wrong while submitting the form.
December 20, 2022
Quantum Leap Healthcare Collaborative Announces Positive Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL in Neoadjuvant Breast Cancer
July 29, 2020
Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial
July 7, 2020
Quantum Leap Healthcare Collaborative Announces the Selection of Byondis' SYD985 in the I-SPY 2 TRIAL for Stage 2/3, High-Risk Breast Cancer
June 8, 2020
QLHC Announces Selection of Sanofi's SAR439859 as oral SERD Backbone Agent in Endocrine Optimization Pilot Study
April 28, 2020
Quantum Leap Healthcare’s I-SPY 2 Investigators, ARDS Experts and COVID R&D Consortium Unite to Bring Success from the I-SPY Adaptive Platform Clinical Trial to COVID-19 ARDS ICU Patients
January 14, 2020
Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer
August 6, 2019
KEYTRUDA’s Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials
October 15, 2018
Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
September 12, 2018
I-SPY 2, an Innovative Clinical Trial Model that is Revolutionizing the Treatment of Early Stage, High-Risk Breast Cancer
September 6, 2018
Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab For The I-SPY 2 Trial For Breast Cancer
December 7, 2017
Long-term efficacy results from the I-SPY 2 TRIAL indicate pathological complete response (pCR) is a powerful predictor for breast cancer survival
December 7, 2017
I-SPY 2 TRIAL predictive biomarker analysis shows promise to improve targeted therapy for high-risk breast cancers
August 21, 2017
Natera's Personalized CtDNA Technology Now Part Of I-SPY 2 TRIAL
June 5, 2017
New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer
October 25, 2016
Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer
July 7, 2016
New England Journal of Medicine Underscores Success of the I-SPY 2 Clinical Trial Model as Promising Results are Published for Two Breast Cancer Drugs Investigated in the Study
April 18, 2016
T-DM1 (Kadcyla) and pertuzumab (Perjeta) Show Promise for Women with HER2-positive Breast Cancer
March 21, 2016
Keytruda, talazoparib join I-SPY 2
June 1, 2015
Merck & Co. MK-2206 "Graduates" From I-SPY 2
December 11, 2014
Plexxikon and QuantumLeap Healthcare Collaborative Announce Selection of PLX3397 for I-SPY 2 TRIAL in Breast Cancer
April 7, 2014
I-SPY 2 Trial Identifies Subset of Breast Cancer Patients Most Likely to Benefit From Neratinib
March 11, 2014
Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer
December 26, 2013
Foundation for the NIH Announces First Results of I-SPY 2 Breast Cancer Clinical Trial
March 17, 2010
The Biomarkers Consortium launches I-SPY 2 breast cancer clinical trial
Don't miss a thing! Get I-SPY results, news and event information delivered right to your inbox.
Sign Up
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.